Experimental pancreatic cancer drug offers new hope in major trial

6abc Philadelphia
1.2K followers
51 Video Views·Jun 1, 2026
Phase 3 results showed the treatment nearly doubled survival for patients with previously treated metastatic pancreatic cancer.
AI Generated·May contain errors
There is new hope this morning in the battle against pancreatic cancer.
Researchers are reporting unprecedented results with a new drug.
They say an experimental pill could keep patients alive for twice as long.
This is a targeted therapy that is taking advantage of the biology of pancreatic cancer.
The cancer has these little genetic mutations.
They're like little light switches.
They're turned on and the cancer is growing.
It's spreading and this drug, it turns off the lights, shrinking the cancer,
helping the patients live better and longer.
It's huge for so many people.
The medication is called duraxaniracid.
In a trial of 500 patients with advanced pancreatic cancer,
the drug reduced the overall risk of death by 60% compared to patients who had only chemotherapy.
Those who took the drug lived substantially longer, for an average of 13 months,
compared to about six and a half months for those who only had chemo.
Experts say the drug could pave the way for a revolution in overall cancer treatment.
There's a lot of excitement and enthusiasm, not just for pancreatic cancer,
but for cancers like lung cancer, which are also really challenging.
The FDA recently fast-tracked approval for the drug.
It allows certain patients to receive it outside of clinical trials.
